JP7159148B2 - Ｔｇｆベータスーパーファミリーホモ多量体およびその使用 - Google Patents

Ｔｇｆベータスーパーファミリーホモ多量体およびその使用 Download PDF

Info

Publication number
JP7159148B2
JP7159148B2 JP2019500446A JP2019500446A JP7159148B2 JP 7159148 B2 JP7159148 B2 JP 7159148B2 JP 2019500446 A JP2019500446 A JP 2019500446A JP 2019500446 A JP2019500446 A JP 2019500446A JP 7159148 B2 JP7159148 B2 JP 7159148B2
Authority
JP
Japan
Prior art keywords
seq
amino acids
heteromultimer
heteromultimers
polypeptides
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2019500446A
Other languages
English (en)
Japanese (ja)
Other versions
JP2019527547A (ja
JP2019527547A5 (enExample
Inventor
ラビンドラ クマール，
アシャ グリンバーグ，
ダイアン エス． サコ，
ロズリーヌ カストンギー，
Original Assignee
アクセルロン ファーマ インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by アクセルロン ファーマ インコーポレイテッド filed Critical アクセルロン ファーマ インコーポレイテッド
Publication of JP2019527547A publication Critical patent/JP2019527547A/ja
Priority to JP2022144508A priority Critical patent/JP2022172479A/ja
Publication of JP2019527547A5 publication Critical patent/JP2019527547A5/ja
Application granted granted Critical
Publication of JP7159148B2 publication Critical patent/JP7159148B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70596—Molecules with a "CD"-designation not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/8509—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic
    • C12N2015/8518—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic expressing industrially exogenous proteins, e.g. for pharmaceutical use, human insulin, blood factors, immunoglobulins, pseudoparticles

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Medicinal Chemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cell Biology (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
JP2019500446A 2016-07-07 2017-07-06 Ｔｇｆベータスーパーファミリーホモ多量体およびその使用 Expired - Fee Related JP7159148B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2022144508A JP2022172479A (ja) 2016-07-07 2022-09-12 Ｔｇｆベータスーパーファミリーホモ多量体およびその使用

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201662359614P 2016-07-07 2016-07-07
US62/359,614 2016-07-07
US201662404670P 2016-10-05 2016-10-05
US62/404,670 2016-10-05
PCT/US2017/040849 WO2018009624A1 (en) 2016-07-07 2017-07-06 Tgf-beta superfamily heteromultimers and uses thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2022144508A Division JP2022172479A (ja) 2016-07-07 2022-09-12 Ｔｇｆベータスーパーファミリーホモ多量体およびその使用

Publications (3)

Publication Number Publication Date
JP2019527547A JP2019527547A (ja) 2019-10-03
JP2019527547A5 JP2019527547A5 (enExample) 2022-09-22
JP7159148B2 true JP7159148B2 (ja) 2022-10-24

Family

ID=60913181

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2019500446A Expired - Fee Related JP7159148B2 (ja) 2016-07-07 2017-07-06 Ｔｇｆベータスーパーファミリーホモ多量体およびその使用
JP2022144508A Pending JP2022172479A (ja) 2016-07-07 2022-09-12 Ｔｇｆベータスーパーファミリーホモ多量体およびその使用

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2022144508A Pending JP2022172479A (ja) 2016-07-07 2022-09-12 Ｔｇｆベータスーパーファミリーホモ多量体およびその使用

Country Status (6)

Country Link
US (1) US20200071382A1 (enExample)
EP (1) EP3481860A4 (enExample)
JP (2) JP7159148B2 (enExample)
AU (2) AU2017293778B2 (enExample)
CA (1) CA3029890A1 (enExample)
WO (1) WO2018009624A1 (enExample)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3280435B1 (en) 2015-04-06 2021-06-02 Acceleron Pharma Inc. Tgf-beta superfamily type i and type ii receptor heteromultimers and uses thereof
MA41919A (fr) 2015-04-06 2018-02-13 Acceleron Pharma Inc Hétéromultimères alk4:actriib et leurs utilisations
CN113683708A (zh) 2015-04-06 2021-11-23 阿塞勒隆制药公司 单臂i型和ii型受体融合蛋白和其用途
AU2017338916B2 (en) 2016-10-05 2022-03-24 Acceleron Pharma Inc. Variant ActRIIB proteins and uses thereof
CN110678195A (zh) 2016-10-05 2020-01-10 阿塞勒隆制药公司 ALK4:ActRIIB异多聚体及其用途
AU2019262139A1 (en) * 2018-05-03 2020-11-26 Acceleron Pharma Inc. Multispecific binders of TGFβ-superfamily ligands and uses thereof
US20220089683A1 (en) * 2018-06-15 2022-03-24 Acceleron Pharma Inc. Bi-and tri-functional fusion proteins and uses thereof
CA3156007A1 (en) 2019-09-27 2021-04-01 Disc Medicine, Inc. METHODS OF TREATING MYELOFIBROSE AND ASSOCIATED CONDITIONS
AU2021273014A1 (en) 2020-05-13 2022-11-17 AbbVie Deutschland GmbH & Co. KG Anti-hemojuvelin (HJV) antibodies for treating anemia of chronic disease
ES3075793T3 (en) 2020-05-13 2026-08-07 Disc Medicine Inc Anti-hemojuvelin (hjv) antibodies for treating myelofibrosis
EP4433160A1 (en) 2021-11-17 2024-09-25 Disc Medicine, Inc. Methods for treating anemia of kidney disease
WO2026125668A1 (en) * 2024-12-13 2026-06-18 Institut National de la Santé et de la Recherche Médicale Peptide derived from endoglin for treating bleeding disorders

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014055869A1 (en) 2012-10-05 2014-04-10 Acceleron Pharma, Inc. Treatment of cancer with alk1 antagonists
JP2014510084A (ja) 2011-03-17 2014-04-24 ラモット・アット・テル・アビブ・ユニバーシテイ・リミテッド 二重特異性および単一特異性の非対称な抗体ならびにそれらの作製方法
WO2015160940A1 (en) 2014-04-15 2015-10-22 President And Fellows Of Harvard College Bi-specific agents

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3549952A1 (en) * 2011-04-20 2019-10-09 Acceleron Pharma Inc. Endoglin polypeptides and uses thereof
AU2014339898B2 (en) * 2013-10-25 2020-07-23 Acceleron Pharma, Inc. Endoglin peptides to treat fibrotic diseases
AU2014388308A1 (en) * 2014-03-28 2016-10-27 Acceleron Pharma, Inc. Use of activin receptor-like kinase 1 (ALK-1) antagonists in the treatment of cancer

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2014510084A (ja) 2011-03-17 2014-04-24 ラモット・アット・テル・アビブ・ユニバーシテイ・リミテッド 二重特異性および単一特異性の非対称な抗体ならびにそれらの作製方法
WO2014055869A1 (en) 2012-10-05 2014-04-10 Acceleron Pharma, Inc. Treatment of cancer with alk1 antagonists
WO2015160940A1 (en) 2014-04-15 2015-10-22 President And Fellows Of Harvard College Bi-specific agents

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
J. Biochem. Mol. Biol.，2011年，vol.286, no.34, p.30034-30046
Molecular Biology of theCell，2015年，vol.26, p.3117-3127

Also Published As

Publication number Publication date
AU2017293778B2 (en) 2022-03-24
AU2017293778A1 (en) 2019-01-24
JP2019527547A (ja) 2019-10-03
EP3481860A4 (en) 2020-01-22
WO2018009624A1 (en) 2018-01-11
CA3029890A1 (en) 2018-01-11
US20200071382A1 (en) 2020-03-05
AU2022201603A1 (en) 2022-03-31
EP3481860A1 (en) 2019-05-15
JP2022172479A (ja) 2022-11-16

Similar Documents

Publication Publication Date Title
JP7617962B2 (ja) バリアントＡｃｔＲＩＩＢタンパク質およびその使用
JP7203807B2 (ja) シングルアームｉ型およびｉｉ型受容体融合タンパク質およびその使用
JP7037363B2 (ja) Ｔｇｆベータスーパーファミリーｉ型およびｉｉ型受容体ヘテロ多量体およびその使用
JP2022172479A (ja) Ｔｇｆベータスーパーファミリーホモ多量体およびその使用
JP7504947B2 (ja) Ｔｇｆ－ベータスーパーファミリーｉ型およびｉｉ型受容体ヘテロ多量体ならびにその使用
JP2019527547A5 (enExample)
JP2023528709A (ja) バリアントａｃｔｒｉｉｂタンパク質およびその使用
HK40078293A (en) Tgf-beta superfamily type i and type ii receptor heteromultimers and uses thereof
HK40057061A (en) Single-arm type i and type ii receptor fusion proteins and uses thereof
EP3735418A1 (en) Single-arm co-receptor fusion proteins and uses thereof
HK1248733B (en) Tgf-beta superfamily type i and type ii receptor heteromultimers and uses thereof
HK1252958B (en) Single-arm type i and type ii receptor fusion proteins and uses thereof
HK1248732B (en) Single-arm type i and type ii receptor fusion proteins and uses thereof
HK40011178A (zh) 变体actriib蛋白及其用途

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200703

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20200703

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20210407

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20210521

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20210708

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20211122

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20220315

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20220614

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20220812

A524 Written submission of copy of amendment under article 19 pct

Free format text: JAPANESE INTERMEDIATE CODE: A524

Effective date: 20220912

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20220926

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20221012

R150 Certificate of patent or registration of utility model

Ref document number: 7159148

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

RD02 Notification of acceptance of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: R3D02

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: R3D04

LAPS Cancellation because of no payment of annual fees